Alberto Benito Boillos-rekin lankidetzan egindako argitalpenak (18)

2024

  1. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment

    Journal of Physiology and Biochemistry

2023

  1. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease

    Journal of Physiology and Biochemistry

2022

  1. A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers

    Panminerva medica, Vol. 64, Núm. 4, pp. 485-496

2021

  1. Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study

    European Journal of Nutrition, Vol. 60, Núm. 4, pp. 1769-1780

  2. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study

    European Journal of Nutrition, Vol. 60, Núm. 6, pp. 3043-3057

  3. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial

    Liver International, Vol. 41, Núm. 7, pp. 1532-1544

  4. Three different genetic risk scores based on fatty liver index, magnetic resonance imaging and lipidomic for a nutrigenetic personalized management of nafld: The fatty liver in obesity study

    Diagnostics, Vol. 11, Núm. 6

2020

  1. Association of the SH2B1 RS7359397 gene polymorphism with steatosis severity in subjects with obesity and non-alcoholic fatty liver disease

    Nutrients, Vol. 12, Núm. 5

2019

  1. Association between Different Animal Protein Sources and Liver Status in Obese Subjects with Non-Alcoholic Fatty Liver Disease: Fatty Liver in Obesity (FLiO) Study

    Nutrients, Vol. 11, Núm. 10

  2. Association between sleep disturbances and liver status in obese subjects with nonalcoholic fatty liver disease: A comparison with healthy controls

    Nutrients, Vol. 11, Núm. 2

  3. The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: The fatty liver in obesity (FLiO) randomized controlled trial

    Nutrients, Vol. 11, Núm. 10

  4. Ultrasound/elastography techniques, lipidomic and blood markers compared to magnetic resonance imaging in non-alcoholic fatty liver disease adults

    International Journal of Medical Sciences, Vol. 16, Núm. 1, pp. 75-83

2018

  1. Interplay of glycemic index, glycemic load, and dietary antioxidant capacity with insulin resistance in subjects with a cardiometabolic risk profile

    International Journal of Molecular Sciences, Vol. 19, Núm. 11

2013

  1. Safety and liver transduction efficacy of raav5-cohpbgd in nonhuman primates: A potential therapy for acute intermittent porphyria

    Human Gene Therapy, Vol. 24, Núm. 12, pp. 1007-1017

2012

  1. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B

    Hepatology, Vol. 56, Núm. 2, pp. 474-483

2010

  1. A phase i clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma

    Cancer Gene Therapy, Vol. 17, Núm. 12, pp. 837-843

2005

  1. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas

    Journal of Clinical Oncology, Vol. 23, Núm. 5, pp. 999-1010

2004

  1. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors

    Journal of Clinical Oncology, Vol. 22, Núm. 8, pp. 1389-1397